Evidence map›Paper›PMID 39749114›Full record

ArticleFrontiers in chemical biology2024

Structural and kinetic characterization of DUSP5 with a Di-phosphorylated tripeptide substrate from the ERK activation loop.

Andrea Imhoff, Noreena L Sweeney, Robert D Bongard, Raulia Syrlybaeva, Ankan Gupta, Edgar Del Carpio, Marat R Talipov, Costanza Garcia-Keller, Debbie C Crans, Ramani Ramchandran and 1 more

Abstract read
In one paragraph

Article in Frontiers in chemical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. ERK autoinhibition mechanism informs a drug combination strategy.Protein science : a publication of the Protein Society · 2026
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andrea ImhoffCenter for Structure-based Drug Design and Development, Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI, United States.
Noreena L SweeneyCenter for Structure-based Drug Design and Development, Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI, United States.
Robert D BongardCenter for Structure-based Drug Design and Development, Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI, United States.
Raulia SyrlybaevaDepartment of Chemistry and Biochemistry, New Mexico State University, MSC 3C, Las Cruces, NM, United States.
Ankan GuptaDepartment of Pediatrics, Division of Neonatology, Children's Research Institute (CRI) Developmental Vascular Biology Program, Translational and Biomedical Research Center, Milwaukee, WI, United States.
Edgar Del CarpioDepartment of Chemistry, Colorado State University, Fort Collins, CO, United States.
Marat R TalipovDepartment of Chemistry and Biochemistry, New Mexico State University, MSC 3C, Las Cruces, NM, United States.
Costanza Garcia-KellerDepartment of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, United States.
Debbie C CransDepartment of Chemistry, Colorado State University, Fort Collins, CO, United States.
Ramani RamchandranDepartment of Pediatrics, Division of Neonatology, Children's Research Institute (CRI) Developmental Vascular Biology Program, Translational and Biomedical Research Center, Milwaukee, WI, United States.
Daniel S SemCenter for Structure-based Drug Design and Development, Department of Pharmaceutical Sciences, Concordia University Wisconsin, Mequon, WI, United States.

Funding

NM-INBRE Sequencing and Bioinformatics CoreP20GM103451 · NIGMS · NEW MEXICO STATE UNIVERSITY LAS CRUCES · PI Charlotte C. Gard · 2012 to 2026
$61.2M
Cilia as a biomarker of CNS vascular healthR33HL154254 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI NAULI, SURYA, PALECEK, SEAN P · 2022 to 2024
$1.9M
Development of ER-beta Agonists to Treat Post-Menopausal Memory DeclineR15GM118304 · NIGMS · CONCORDIA UNIVERSITY WISCONSIN · PI SEM, DANIEL S · 2015 to 2018
$820k
NHLBI NIH HHS R33 HL154254NIGMS NIH HHS P20 GM103451NIGMS NIH HHS R15 GM118304
6 · The paper itself

Abstract

Introduction: Dual specific phosphatases (DUSPs) are mitogen-activated protein kinase (MAPK) regulators, which also serve as drug targets for treating various vascular diseases. Previously, we have presented mechanistic characterizations of DUSP5 and its interaction with pERK, proposing a dual active site. Methods: Herein, we characterize the interactions between the DUSP5 phosphatase domain and the pT-E-pY activation loop of ERK2, with specific active site assignments. We also report the full NMR chemical shift assignments of DUSP5 that now enable chemical shift perturbation and dynamics studies. Results and Discussion: Both phosphates of the pT-E-pY tripeptide are dephosphorylated, based on Summary: These studies indicate a preference for pY before pT binding, but with ability to bind and dephosphorylate both residues, and with a dynamic active site pocket that accommodates multiple tripeptide orientations.

Indexed as

dual active siteDUSP5enzyme kineticspERKphosphatasephosphorylated peptide substratesregulationvanadate

Identifiers

PMID39749114
PMCPMC11694514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.